GlassScriptPhysician profile
Aamir Hussain
NPI 1558529404
$50,588.06
in general payments reported to CMS, 2019-2025
27 companies · $78.16 in 2025
The $78.16 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $29K · 2021: $8,210 · 2022: $9,079 · 2023: $3,467 · 2024: $396 · 2025: $78.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,940 · Food and Beverage: $998 · Education: $4.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,940.00 |
| Food and Beverage | $997.67 |
| Education | $4.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27,785.96 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $19,326.90 | 2019-2024 | Soliris, Ultomiris |
| Argenx US, INC. | $1,381.87 | 2022-2023 | Vyvgart |
| Abbvie INC. | $774.47 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $156.56 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $155.73 | 2019-2025 | |
| Lilly USA, LLC | $147.76 | 2019-2024 | Amyvid |
| Acorda Therapeutics, INC | $143.96 | 2019 | |
| Genzyme Corporation | $82.12 | 2019-2022 | |
| Biogen, INC. | $80.77 | 2019-2022 | |
| Pfizer INC. | $76.67 | 2023-2025 | |
| Amgen INC. | $57.57 | 2019-2020 | |
| Lundbeck LLC | $48.79 | 2019-2020 | |
| Kyowa Kirin, INC. | $41.82 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $40.79 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $35.55 | 2019 | |
| Sunovion Pharmaceuticals INC. | $35.44 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $32.63 | 2021 | |
| Ucb, INC. | $32.37 | 2022-2023 | Briviact |
| Eisai INC. | $30.94 | 2022-2023 | |
| Mdd US Operations, LLC | $27.79 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $20.09 | 2023 | Austedo |
| Bausch Health US, LLC | $16.25 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.16 | 2019 | |
| Promius Pharma LLC | $14.76 | 2019 | |
| Merz North America, INC. | $12.48 | 2019 | |
| Acadia Pharmaceuticals INC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.